Climb Bio Investor Relations Material
Latest events
M&A Announcement
Climb Bio
Q2 2025
12 Aug, 2025
Q1 2025
14 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Climb Bio Inc
Access all reports
Eliem Therapeutics, Inc. is a biotechnology company focused on developing therapies for neuronal excitability disorders, which are associated with conditions like chronic pain, epilepsy, depression, and anxiety. The company’s approach involves advancing clinical-stage compounds that target neurological diseases, aiming to address significant unmet medical needs. Eliem Therapeutics is headquartered in Wilmington, Delaware, and its shares are listed on the NASDAQ.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
CLYM
Country
🇺🇸 United States